Free Trial
NASDAQ:KRRO

Korro Bio Q4 2024 Earnings Report

Korro Bio logo
$13.80 -1.01 (-6.82%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$14.22 +0.42 (+3.07%)
As of 05/23/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio EPS Results

Actual EPS
-$2.26
Consensus EPS
-$2.33
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Korro Bio Revenue Results

Actual Revenue
$2.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Korro Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 18, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Korro Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Korro Bio Earnings Headlines

FY2025 EPS Forecast for Korro Bio Decreased by Analyst
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Korro Bio to Cut 20% of Workforce
Korro Bio to Cut 20% of Workforce
See More Korro Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email.

About Korro Bio

Korro Bio (NASDAQ:KRRO), a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Korro Bio Profile

More Earnings Resources from MarketBeat